

Ezio Bonvini, Macrogenics Inc: Profile & Biography - Bloomberg


































































  

























Feedback





Ezio Bonvini

Senior VP:Research/Chief Scientific Ofcr,
Macrogenics Inc






Career History




Senior VP:Research/Chief Scientific Ofcr
Macrogenics Inc, 9/2016-PRESENT


Senior VP:Research
Macrogenics Inc, UNKNOWN-9/2016



Macrogenics Inc, 6/2003-UNKNOWN



Fda, FORMER



Hhs Nih National Cancer Institute, FORMER


Chief:Immunobiology
Cber, FORMER


Show More









Website:
www.macrogenics.com






Corporate Information
Address:

9640 Medical Center Drive
Rockville, MD 20850
United States


Phone:
1-301-251-5172


Fax:
1-301-251-5321


Web url:
www.macrogenics.com











From The Web












Personal Information



Education



 Scientific Lyceum
Graduated, Science


Universita DI Genova
MD








Sponsored Financial Commentaries







More From The Web


















Home


News


Top Headlines
Most Popular
Exclusive
Law
Entrepreneurs
Leaders
Economy
Environment
Science
Sports
Markets Magazine
Pursuits Magazine
Bloomberg Visual Data
Bloomberg Best (and Worst)
For comments or complaints about news coverage click here


Regions
U.S.
China
Europe
Asia
U.K. & Ireland
Australia & New Zealand
Canada
India & Pakistan
Japan
Africa
Eastern Europe
Latin America
Middle East
Markets
Commodities
Currencies
Bonds
Stocks
Energy Markets
Municipal Bonds
Emerging Markets
Funds
Islamic Finance
Industries
Energy
Technology
Real Estate
Finance
Health Care
Transportation
Insurance
Retail
Media
Manufacturing




Quick


Market Data


Stocks
Stock Futures
World Indexes
Americas
Europe, Middle East, & Africa
Asia-Pacific
Gainers & Losers
Earnings Calendar
Industry Leaders
Currencies
Americas
Europe, Middle East, & Africa
Asia-Pacific
Foreign Exchange Cross Rates
FX Fixings
Currency Converter
Forex Trading Videos
Commodities
Energy Prices
Metals Prices
Agricultural Prices


Rates & Bonds
US Treasuries
UK Gilts
Germany Bunds
Japan Bonds
Australia Bonds
Bloomberg Bond Indexes
Corporate Bonds
Consumer Rates
Economic Calendar
Watchlist
European Debt Crisis
Symbol Search
The Market Now




Personal Finance


Top Headlines
Saving & Investing
Real Estate
Retirement Planning
Financial Advisers
Taxes
Blog: Ventured & Gained
Real Cost Of
Money Gallery
Calculators
Watchlist (Portfolio Tracker)




Tech


Top Headlines
Social Media
Mobile & Wireless
Web
Enterprise Tech
TV, Games & Movies
Apple
Tech Deals
Global Tech
Slideshows
Videos




U.S. Politics


Sustainability


Top Headlines
Energy
Corporate Sustainability
Policy
Natural Resources
Health & Population
Slideshows
Videos
Blog: The Grid




Luxury


Top Headlines
Autos
Billionaires
Living
Property
Travel
Well Spent
Loot Blog
Pursuits Magazine
Videos




TV


Live TV
Channel Finder
Personalities
Apple TV
iPad App
Schedule
U.S.
Asia
Europe


Shows
Surveillance
Market Makers
Lunch Money
Street Smart
Bloomberg West
Game Changers




Video


Must See
Latest
Live TV
Shows
Playlist




Radio


Live Radio
Shows
Schedule
Personalities
Podcasts
Bloomberg Brief
Featured Podcasts and New Shows
Bloomberg View
Masters in Business
First Word
Surveillance
Bloomberg Advantage
In the Loop
Bloomberg Law
Taking Stock
Bloomberg Best
More Podcasts




Blogs


Global Tech
The Grid
Loot
The Market Now
Political Capital
Tech Deals
Ventured and Gained




Opinion




My Saved



Registration



Sign In



Bloomberg.com



Businessweek.com



Company



About
Blog
Careers
Diversity & Inclusion
News Mission
Philanthropy & Engagement
Press Room
Procurement
Sustainability




Products



Financial Products
Bloomberg Professional Service
Bloomberg Anywhere
Bloomberg Tradebook
Bloomberg Briefs
Bloomberg Indexes
Bloomberg SEF
Service Center
Customer Support
Enterprise Products
Enterprise Solutions
Trading Solutions
Industry Products
Bloomberg BNA
Bloomberg Government
Bloomberg Law
Bloomberg Link
Bloomberg New Energy Finance
Bloomberg Sports
Content Licensing




Bloomberg Anywhere



Mobile Apps



Bloomberg Visual Data































 



Ezio Bonvini, Senior Vice President, Research, Macrogenics Inc | Spoke











































LOGIN



REGISTER








Add Company



Add Person



Add Topic




Login






Or



















Home | People | Ezio Bonvini


Advanced Search
FAQ




Javascript is disabled












Bio
EDIT













Ezio Bonvini

M. Enzio Bonvini, M. Ezio Bonvini



Senior Vice President, Research, Macrogenics Inc




Rockville, MD




Find other people named Ezio Bonvini




General Info


Medical and Diagnostic Laboratories



Add Tags— eg, Finance, Business2Business...



Ezio Bonvini, M.D., Senior Vice President, Research
 Dr. Bonvini comes to MacroGenics with 24 years of research, regulatory and clinical trial design experience spent at the National Cancer Institute, the National Institutes of Health, and more recently at the Food and Drug Administration (FDA) in the Center for Biologics Evaluation and Research (CBER), which is responsible for regulating therapeutic monoclonal antibodies and other proteins. Dr. Bonvini’s research dealt with the molecular mechanism of signal transduction by immune receptors in leukocyte activation. During his tenure at CBER, he held several leadership positions in the Division of Monoclonal Antibodies, most recently as the Acting Deputy Division Director and Chief of the Laboratory of Immunobiology, where he was responsible for supervising the research program and the review of monoclonal antibody products from IND to BLA stages. While at the FDA, Dr. Bonvini received several awards for his scientific and regulatory work. His familiarity with all aspects of scientific, regulatory, and clinical development process for biologics will help focus MacroGenics R&D development of FDA-compliant product candidates from the earliest stages of preclinical development. Dr. Bonvini received a Diploma in Science from the Scientific Lyceum in Genoa, Italy, and his M.D., summa cum laude, and Specialty Certification in Clinical Hematology from the University of Genoa, School of Medicine, in Genoa, Italy.


Not who you're looking for?
Find other Ezio Bonvinis on Spoke




Contact



Telephone



Email



Background Report



Public Records


powered by





Digital Info



www.macrogenics.com/



N/A



N/A



N/A



N/A



N/A



N/A









Resume

EDIT
CAREER



Macrogenics Inc

Senior Vice President, Research





EDUCATION

EDIT

Add a Degree— eg, Bachelors in Business Administration








Blogs By Industry Voices


There are currently no Blogs by Industry Voices





Achievements and Recognition
EDIT


Add an achievement and/or recognition— eg, Man of the year, Forbes 2011...





Notable Links

EDIT


The links below are powered by Bing search results. Click edit to customize.





Videos
EDIT


Add a videofrom youtube or vimeo





EXECUTIVES & FEATURED PEOPLE AT Macrogenics Inc








Kathryn Stein

Senior Vice President, Product Development & Regulatory Affairs









Ezio Bonvini










Robert Obst

Vice President, Human Resources & Operations









Nelson Campbell

Senior Vice President and Chief Financial Officer









Ronald Wilder

Vice President, Clinical Research









Joseph Panigot

Vice President, Legal Affairs









Sujata Vijh










David Carlin

Vice President, Biostatistics & Data Management









Scott Koenig

Chief Executive Officer









Valerie Austin

Executive Assistant
















Created on Jun 06, 2011


by Spoke
 







Edited on Jun 06, 2011


by Spoke
 




PAGE COMPLETION

40%




Website/Blog




Industry




Career




Summary




Add Education



Add a Video



Add a Social Network



Add 3 Achievements



Add a Photo



Add 3 Notable Links



View More


View Less



SHARE THIS PAGE
















Add Page


Add Company
Add Person
Add Topic




Copy this code to embed a widget:



<div id="spoke-root"></div>
<script>(function(d, s, id) {
var js, sjs = d.getElementsByTagName(s)[0];
if (d.getElementById(id)) return;
js = d.createElement(s); js.id = id;
js.src = "//www.spoke.com/assets/widget.js";
sjs.parentNode.insertBefore(js, sjs);
}(document, 'script', 'spoke-widget-js'));</script>
    <div class="spoke-widget" data-host="//www.spoke.com" data-type="person" data-id="3e1429c09e597c1002ad232e" data-width="404" data-height="230" data-scroll="no" data-frame-border="none"></div>
    <div style="font-size: 9pt;"><a href="http://www.spoke.com/people/ezio-bonvini-3e1429c09e597c1002ad232e">Ezio Bonvini</a> widget provided by <a href="http://www.spoke.com">Spoke</a></div>




Public Records
Our partner can help you find public records for Ezio.


More on









Some of Spoke's Content Providers








Become a Spoke Content Provider
Learn More




Ezio Bonvini M.D.: Executive Profile & Biography - Bloomberg









































  





















































































July 27, 2017 12:40 AM ET
Biotechnology

Company Overview of MacroGenics, Inc.



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Ezio   Bonvini M.D.Chief Scientific Officer and Senior Vice President of Research, MacroGenics, Inc.AgeTotal Calculated CompensationThis person is connected to 0 Board Members in 0 different organizations across 1 different industries.63$1,018,793As of Fiscal Year 2016
Background

		Dr. Ezio Bonvini, M.D.,  has been Chief Scientific  Officer and Senior Vice President of Research at MacroGenics, Inc. since September 2016. Dr. Bonvini served as Vice President of Clinical Research at MacroGenics, Inc. Dr. Bonvini, a hematologist by training, is an expert in immunobiology and joined MacroGenics since June 2003 and served as Vice President of Research since November 2004. He joined MacroGenics, Inc. in June 2003. He has MacroGenics with 24 years of research, ... regulatory and clinical trial design experience spent at the National Cancer Institute, the National Institutes of Health and more recently at the Food and Drug Administration (FDA) in the Center for Biologics Evaluation and Research (CBER), which is responsible for regulating therapeutic monoclonal antibodies and other proteins. Dr. Bonvinis research dealt with the molecular mechanism of signal transduction by immune receptors in leukocyte activation. During his tenure at CBER, he held several leadership positions in the Division of Monoclonal Antibodies, most recently as the Acting Deputy Division Director and Chief of the Laboratory of Immunobiology, where he was responsible for supervising the research program and the review of monoclonal antibody products from IND to BLA stages. While at the FDA, he received several awards for his scientific and regulatory work. His familiarity with all aspects of scientific, regulatory and clinical development process for biologics will help focus MacroGenics R&D development of FDA-compliant product candidates from the earliest stages of preclinical development. Dr. Bonvini received a Diploma in Science from the Scientific Lyceum in Genoa, Italy and his M.D. and Specialty Certification in Clinical Hematology from the University of Genoa, School of Medicine.Read Full Background




Corporate Headquarters
9704 Medical Center DriveRockville, Maryland 20850United StatesPhone: 301-251-5172Fax: 301-251-5321
Board Members Memberships
				There is no Board Members Memberships data available.
				Education
MD School Of Medicine And Surgery, University Of Genoa
Other Affiliations
School Of Medicine And Surgery, University Of Genoa


Annual Compensation
Salary$369,627Total Annual Compensation$369,627
Stocks Options
All Other Compensation$7,950Exercised Options$33,127Exercised Options Value$632,727Exercisable Options$108,645Unexercisable Options$104,014Total Value of Options$632,727Total Number of Options$245,786
Total Compensation
Total Annual Cash Compensation$492,644Total Short Term Compensation$369,627Other Long Term Compensation$7,950Total Calculated Compensation$1,018,793




Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONThere is no Competitor Compensation data available.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact MacroGenics, Inc., please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close





























MGNX Ezio Bonvini Insider Trades for Macrogenics Inc.


































Bulletin






Investor Alert







Tokyo Markets Close in:



Currencies
Europe Markets
London Markets


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Macrogenics Inc.

                  NASDAQ: MGNX
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Macrogenics Inc.



After Hours
 --Quotes are delayed by 20 min
Jul 26, 2017, 4:42 p.m.


MGNX

/quotes/zigman/21477642/composite


$
17.38




Change

0.00
0.00%

Volume
Volume 2,097
Quotes are delayed by 20 min








/quotes/zigman/21477642/composite
Previous close

$
			17.48
		


$
				17.38
			
Change

-0.10
-0.57%





Day low
Day high
$17.22
$17.54










52 week low
52 week high

            $16.63
        

            $33.30
        


















Insider Activity


Individual




Ezio Bonvini



Dr. Ezio Bonvini, MD, is Chief Scientific Officer & Senior VP-Research at MacroGenics, Inc. Dr. Bonvini was previously employed as Deputy Director-Division by Center For Biologics Evaluation & Research, a Principal by National Cancer Institute, a Principal by National Institutes of Health, and a Principal by US Food & Drug Administration. He received his doctorate degree from the University of Genoa School of Medicine.



Transactions


Date
Shares
Transaction
Value





10/19/2016
5,349


 
Derivative/Non-derivative trans. at $0.94 per share.


5,028


10/19/2016
5,349


 
Derivative/Non-derivative trans. at $0.94 per share.


5,028


02/11/2016
11,962


 
Derivative/Non-derivative trans. at $0.94 per share.


11,244


01/07/2016
8,895


 
Derivative/Non-derivative trans. at $0.94 per share.


8,361


01/07/2016
4,421


 
Derivative/Non-derivative trans. at $0.94 per share.


4,155


11/16/2015
3,117


 
Disposition at $31.44 per share.


97,999


10/15/2015
6,233


 
Disposition at $25.21 per share.


157,134


10/13/2015
14,521


 
Derivative/Non-derivative trans. at $25.53 per share.


370,722


10/13/2015
14,521


 
Derivative/Non-derivative trans. at $0.71 per share.


10,309


10/02/2015
5,893


 
Derivative/Non-derivative trans. at $0.94 per share.


5,539


10/02/2015
11,984


 
Derivative/Non-derivative trans. at $0.94 per share.


11,264


09/22/2015
7,550


 



0


09/22/2015
7,550


 
Gift at $0 per share.


0


09/18/2015
7,000


 
Derivative/Non-derivative trans. at $0.94 per share.


6,580


09/16/2015
4,000


 
Derivative/Non-derivative trans. at $0.94 per share.


3,760


08/27/2015
5,000


 
Derivative/Non-derivative trans. at $0.94 per share.


4,700


08/26/2015
5,000


 
Derivative/Non-derivative trans. at $0.94 per share.


4,700


08/10/2015
4,000


 
Derivative/Non-derivative trans. at $0.94 per share.


3,760


07/10/2015
2,400


 
Disposition at $38.09 per share.


91,416


07/10/2015
2,400


 
Derivative/Non-derivative trans. at $0.71 per share.


1,704


06/30/2015
6,497


 
Disposition at $38.07 per share.


247,341


06/30/2015
6,497


 
Derivative/Non-derivative trans. at $0.71 per share.


4,612


06/24/2015
6,097


 
Disposition at $38.08 per share.


232,174


06/24/2015
6,097


 
Derivative/Non-derivative trans. at $0.71 per share.


4,328


06/23/2015
13,054


 
Disposition at $38.14 per share.


497,880


06/23/2015
13,054


 
Derivative/Non-derivative trans. at $0.71 per share.


9,268


06/15/2015
6,233


 
Disposition at $34.01 per share.


211,985


06/15/2015
6,233


 
Derivative/Non-derivative trans. at $0.71 per share.


4,425


05/15/2015
6,233


 
Disposition at $30.24 per share.


188,486


05/15/2015
6,233


 
Derivative/Non-derivative trans. at $0.71 per share.


4,425


04/15/2015
6,233


 
Disposition at $33.98 per share.


211,798


04/15/2015
6,233


 
Derivative/Non-derivative trans. at $0.71 per share.


4,425


11/14/2014
3,900


 
Derivative/Non-derivative trans. at $0.71 per share.


2,769


10/10/2014
400


 
Derivative/Non-derivative trans. at $0.71 per share.


284


10/09/2014
2,663


 
Derivative/Non-derivative trans. at $0.71 per share.


1,890


10/08/2014
1,597


 
Derivative/Non-derivative trans. at $0.94 per share.


1,501





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Dr. Scott E. Koenig 
President, Chief Executive Officer & Director




Mr. James  Karrels 
Chief Financial Officer, Secretary & Senior VP




Dr. Ezio  Bonvini 
Chief Scientific Officer & Senior VP-Research




Dr. Jon  Wigginton 
Chief Medical Officer & SVP-Clinical Development




Mr. Eric  Risser 
Chief Business Officer & SVP-Business Development




Dr. Thomas M. Spitznagel 
SVP-BioPharmaceutical Development & Manufacturing




Dr. Syd  Johnson 
Vice President-Antibody Engineering




Mr. Robert  Dallimore 
Vice President-Quality




Dr. Paul A. Moore 
Vice President-Immunology & Cell Biology




Mr. Scott T. Jackson 
Director




Dr. Karen Jean Ferrante 
Director




Ms. Lynn  Cilinski 
Treasurer, Vice President & Controller




Mr. Robert  Obst 
Vice President-Human Resources & Facilities




Mr. Joseph  Panigot 
Vice President-Legal Affairs




Mr. Paulo F. Costa 
Chairman




Dr. David C. Stump 
Independent Director




Mr. Kenneth H. Galbraith 
Independent Director




Mr. Ed M. Hurwitz 
Independent Director




Mr. Matthew K. Fust 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




12:40 AM EDT
July 27, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Open





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
12:01a5 cities where people are making ridiculous money when they sell their homes
10:44pAmericans in this field have the highest rate of divorce by age 30
10:44pThese cash-strapped couples want total strangers to pay for their weddings
9:56pThis social network ranks as the worst for young people’s mental health (it’s not Facebook)
9:55pMove over, breathalyzers; ‘textalyzers’ could be used on drivers’ phones 
9:55pThis is the worst mistake people make at work
9:54pCities to move to if you want to work in tech — NOT including San Francisco
9:54pWhat Donald Trump’s battle of wills with Jeff Sessions teaches you about a difficult boss
9:50pWatch out for these surprise charges at the ER
9:49pThe open road or the open skies? Millennials choose the former...
9:48pHow an online wedding registry in my name appeared out of thin air
9:47pDon’t have a college degree? These are the industries with the best-paid jobs
9:46pThe highest paid athletes in the world, in one chart
9:46pHow to teach your kids to be better with money than you are
9:40pBack-to-school shopping goes mainstream with deals on eyewear, fitness apparel and kitchen appliances
9:39pSamsung posts record profits on back of strong Galaxy S8 sales
9:39pThe dark side of cruises
9:37pFor transgender Americans, workplace discrimination isn’t limited to the military
7:46pScaramucci on Washington back stabbers: ‘I’m more of a front-stabbing person’
7:43pFacebook keeps warning about growth, but growth doesn’t stop
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,711.01

+97.58
+0.45%





nasdaq

/quotes/zigman/12633936/realtime
6,422.75

+10.57
+0.16%





s&p 500

/quotes/zigman/3870025/realtime
2,477.83

+0.70
+0.03%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15



























































Insider Trading - Bonvini Ezio - Form 4 SEC Filings












Home |
Archives |
Products |
About |
Contact |
FAQ |



New User?
Sign Up | 
Sign In









Form 4 Filings


Insider Buys


Significant Buys


Penny StocksInsider Buying


Insider Sales




Insider Buy Sell Ratios


Stock Options


Insider TradingStock Screener


Insider TradingGraph View


Insider Watch





Sec Filings Insider Trading - Bonvini Ezio





Select Time period: 
1 Month
2 Months
3 Months
6 Months
1 Year
2 Years
3 Years
4 Years
All Data
 

     



google

   



yahoo!



Send this page to:  

Blog
  



Digg

  



Reddit

  



Facebook

  



Stumble

  



del.icio.us








Enter Stock Ticker Symbol or Cik:




Cik Lookup...






Search By Company or Insider Name:







"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch ==>>

What is insider trading>>



Email a friend >>...







Historical filings delayed by 6 months. New user?
Sign Up for real time data.
Existing user?
Sign In

Common stock purchase or sale:



TransactionDate
ReportedDate
Company
Symbol
InsiderRelationship
SharesTraded
AveragePrice
TotalAmount
SharesOwned
Filing




2015-11-16Sale
2015-11-173:22 pm
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
3,117
$31.44
$97,998
70,317(Direct)
View


2015-10-15Sale
2015-10-193:01 pm
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
6,233
$25.21
$157,134
73,434(Direct)
View


2015-07-10Sale
2015-07-133:23 pm
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
2,400
$38.09
$91,416
39,190(Direct)
View


2015-06-30Sale
2015-07-014:27 pm
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
6,497
$38.07
$247,341
43,287(Direct)
View


2015-06-24Sale(A)
2015-07-014:27 pm
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
6,097
$38.08
$232,174
42,887(Direct)
View


2015-06-23Sale(A)
2015-07-014:27 pm
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
13,054
$38.14
$497,880
49,844(Direct)
View


2015-06-24Sale
2015-06-253:39 pm
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
6,097
$38.08
$232,174
17,639(Direct)
View


2015-06-23Sale
2015-06-243:07 pm
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
13,054
$38.14
$497,880
23,736(Direct)
View


2015-06-15Sale
2015-06-161:28 pm
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
6,233
$34.01
$211,984
43,023(Direct)
View


2015-05-15Sale
2015-05-184:15 pm
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
6,233
$30.24
$188,486
48,802(Direct)
View


2015-04-15Sale
2015-04-1611:12 am
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
6,233
$33.98
$211,797
55,035(Direct)
View




 (A) Indicate amendment filing.
 Stock options: Exercise, Award, Grant, Conversion



TransactionDate
ReportedDate
ExercisableExpiration
Company
Symnbol
InsiderRelationship
SharesTraded
ConversionPrice
SharesOwned
Filing




2016-02-11Exercise
2016-10-217:19 pm
N/AN/A
Macrogenics Inc
MGNX
Bonvini EzioSr VP, Research & CSO
11,962
$0.94
100,944(Direct)
View


2016-02-11Exercise
2016-10-217:19 pm
N/AN/A
Macrogenics Inc
MGNX
Bonvini EzioSr VP, Research & CSO
5,349
$0.94
100,944(Direct)
View


2016-02-11Exercise
2016-10-217:19 pm
2011-07-092021-01-08
Macrogenics Inc
MGNX
Bonvini EzioSr VP, Research & CSO
10,653
$0.94
100,944(Direct)
View


2016-02-11Exercise
2016-10-217:19 pm
2010-07-102020-01-09
Macrogenics Inc
MGNX
Bonvini EzioSr VP, Research & CSO
1,309
$0.94
100,944(Direct)
View


2016-02-11Exercise
2016-10-217:19 pm
2010-07-102020-01-09
Macrogenics Inc
MGNX
Bonvini EzioSr VP, Research & CSO
5,349
$0.94
100,944(Direct)
View


2016-09-14Option Award
2016-09-166:10 pm
N/A2026-09-14
Macrogenics Inc
MGNX
Bonvini EzioSr VP, Research & CSO
30,000
$28.94
30,000(Direct)
View


2016-01-07Exercise
2016-01-111:39 pm
N/AN/A
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
4,421
$0.94
83,633(Direct)
View


2016-01-07Exercise
2016-01-111:39 pm
N/AN/A
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
8,895
$0.94
83,633(Direct)
View


2016-01-07Exercise
2016-01-111:39 pm
2009-07-112019-01-09
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
4,421
$0.94
83,633(Direct)
View


2016-01-07Exercise
2016-01-111:39 pm
2009-07-112019-01-10
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
8,895
$0.94
83,633(Direct)
View


2015-12-18Option Award
2015-12-221:11 pm
N/A2025-12-18
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
55,000
$31.43
55,000(Direct)
View


2015-10-13Exercise
2015-10-152:37 pm
N/AN/A
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
14,521
$0.71
94,188(Direct)
View


2015-10-13Exercise
2015-10-152:37 pm
N/AN/A
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
14,521
$25.53
94,188(Direct)
View


2015-10-13Exercise
2015-10-152:37 pm
2005-09-242016-03-23
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
14,521
$0.71
94,188(Direct)
View


2015-10-02Exercise
2015-10-062:19 pm
N/AN/A
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
11,984
$0.94
79,667(Direct)
View


2015-10-02Exercise
2015-10-062:19 pm
N/AN/A
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
5,893
$0.94
79,667(Direct)
View


2015-10-02Exercise
2015-10-062:19 pm
2007-07-072017-01-06
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
5,893
$0.94
79,667(Direct)
View


2015-10-02Exercise
2015-10-062:19 pm
2008-07-062018-01-05
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
11,984
$0.94
79,667(Direct)
View


2015-09-18Exercise
2015-09-223:19 pm
N/AN/A
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
7,000
$0.94
61,790(Direct)
View


2015-09-18Exercise
2015-09-223:19 pm
2007-07-072017-01-06
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
7,000
$0.94
61,790(Direct)
View


2015-09-16Exercise
2015-09-1810:33 am
N/AN/A
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
4,000
$0.94
54,790(Direct)
View


2015-09-16Exercise
2015-09-1810:33 am
2007-07-072017-01-06
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
4,000
$0.94
54,790(Direct)
View


2015-08-26Exercise
2015-08-2811:30 am
N/AN/A
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
5,000
$0.94
50,790(Direct)
View


2015-08-26Exercise
2015-08-2811:30 am
N/AN/A
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
5,000
$0.94
50,790(Direct)
View


2015-08-26Exercise
2015-08-2811:30 am
2007-07-072017-01-06
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
5,000
$0.94
50,790(Direct)
View


2015-08-26Exercise
2015-08-2811:30 am
2007-07-072017-01-06
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
5,000
$0.94
50,790(Direct)
View


2015-08-10Exercise
2015-08-1108:41 am
N/AN/A
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
4,000
$0.94
40,790(Direct)
View


2015-08-10Exercise
2015-08-1108:41 am
2007-07-072017-01-06
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
4,000
$0.95
40,790(Direct)
View


2015-07-10Exercise
2015-07-133:23 pm
N/AN/A
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
2,400
$0.71
39,190(Direct)
View


2015-07-10Exercise
2015-07-133:23 pm
2005-09-242016-03-23
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
2,400
$0.71
39,190(Direct)
View


2015-06-30Exercise
2015-07-014:27 pm
N/AN/A
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
6,497
$0.71
43,287(Direct)
View


2015-06-30Exercise
2015-07-014:27 pm
2005-09-242016-03-23
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
6,497
$0.71
43,287(Direct)
View


2015-06-24Exercise
2015-07-014:27 pm
N/AN/A
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
6,097
$0.71
42,887(Direct)
View


2015-06-24Exercise
2015-07-014:27 pm
2005-09-242016-03-23
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
6,097
$0.71
42,887(Direct)
View


2015-06-23Exercise
2015-07-014:27 pm
N/AN/A
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
13,054
$0.71
49,844(Direct)
View


2015-06-23Exercise
2015-07-014:27 pm
2005-09-242016-03-23
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
13,054
$0.71
49,844(Direct)
View


2015-06-15Exercise
2015-06-161:28 pm
N/AN/A
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
6,233
$0.71
43,023(Direct)
View


2015-06-15Exercise
2015-06-161:28 pm
2005-09-242016-03-23
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
6,233
$0.71
43,023(Direct)
View


2015-05-15Exercise
2015-05-184:15 pm
N/AN/A
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
6,233
$0.71
48,802(Direct)
View


2015-05-15Exercise
2015-05-184:15 pm
2005-09-242016-03-23
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
6,233
$0.71
48,802(Direct)
View


2015-04-15Exercise
2015-04-1611:12 am
N/AN/A
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
6,233
$0.71
55,035(Direct)
View


2015-04-15Exercise
2015-04-1611:12 am
2005-09-242016-03-23
Macrogenics Inc
MGNX
Bonvini EzioSenior VP, Research
6,233
$0.71
55,035(Direct)
View









    © 2005-2017 SecForm4.Com All rights reserved.
    Archives:
    2017 2016 2015 2014 2013 2012 ... 
    Wed, 26 Jul 2017 23:40:08 -0500
  

    SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
    SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC).
Terms of Use |
    Privacy Statement |
  











Ezio  Bonvini - Potomac, MD | Intelius



























Sign In



We found Ezio  Bonvini in Potomac, MD


Ezio  Bonvini

                                                                           Intelius found that Ezio  Bonvini  is  a male between 60 and 70 years old from Potomac, MD.  We have connected them to
                6 addresses,
                3 phones,
                and 2 relatives or associates.
         






Get Report Now

Age

Ezio  Bonvini is in his 60s

Ezio Has Lived In

Potomac, MD
Bethesda, MD
Rockville, MD

Ezio's Relatives

Claudia Palena
Palena Mercedes







Ezio  Bonvini



Zodiac SignAquarius



GenderMale



Professional Status
Vice President Engineering at MacroGenics Inc



Get Report Now










Want to know more about Ezio? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about Ezio, or use our people search engine to find others.
Get Background Check on Ezio  Bonvini
Get a Criminal Check on Ezio  Bonvini
Get a Public Record Report on Ezio  Bonvini
Get a People Search Report on Ezio  Bonvini


Ezio  Bonvini's Contact Information
Known Cities Lived In
Find out where Ezio  Bonvini has lived as well as Ezio  Bonvini's phone numbers and email addresses.




Ezio  Bonvini Has Lived in 2 States
Maryland Address for Ezio  Bonvini


11136 P***** H*** D* 

Potomac, MD


Has Lived In

Potomac, MD
Bethesda, MD


Get Full Address Report










Phone Numbers Associated with Ezio  Bonvini

(301) ***-**** - Rockville, MD 
(301) ***-**** - South San Francisco, CA 
(301) ***-**** - Rockville, MD 


Get Full Phone Report



Email Addresses Associated with Ezio  Bonvini

b******e@***.com
e******i@***.net
e******i@***.com


Get Email Report




Ezio  Bonvini's Professional Information
Information regarding Ezio  Bonvini's professional history.  Find out previous places Ezio  Bonvini has worked as well as dates employed.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Ezio  Bonvini Has Worked at 8 Places
Company: MacroGenics Inc
               Title: Vice President Engineering
Company: MacroGenics Inc
               Title: Senior Vice President Research
Ezio  Bonvini's Experience
Title: Vice President Engineering
               Company: MacroGenics Inc
Job Details
               Company Size: $1 mil to less than $5 mil - Employee Range: Less than 25
Title: Senior Vice President Research
               Company: MacroGenics Inc
Job Details
               Company Size: $100 mil to less than $250 mil - Employee Range: 100 to less than 500
Additional Professional Information on Ezio  Bonvini

 See Ezio  Bonvini's LinkedIn Profile



Ezio  Bonvini's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for Ezio  Bonvini


Ezio  Bonvini's known Social Networks And Potential Email Matches

Find all of Ezio  Bonvini's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
Ezio Bonvini
Username Matches

                  EzioBonvini
                  BonviniEzio
                  Ezio.Bonvini
                  Bonvini.Ezio
                  Ezio_Bonvini
                  Bonvini_Ezio
                  Ezio-Bonvini
                  Bonvini-Ezio
                  EBonvini
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
E Bonvini







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.











    Ezio Bonvini | MacroGenics Inc | ZoomInfo.com



Publications Authored by Ezio Bonvini | PubFacts.com








































Ezio Bonvini
 Are you  Ezio Bonvini?   Register this Author




Register this Author






University of Texas Southwestern Medical CenterUnited States 






Toggle navigation










Publications
















Publications
















33Publications


436Reads



 OF 






















MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies.
Authors:
Liqin Liu,
Chia-Ying K Lam,
Vatana Long,
Lusiana Widjaja,
Yinhua Yang,
Hua Li,
Linda Jin,
Steve Burke,
Sergey Gorlatov,
Jennifer Brown,
Ralph Alderson,
Margaret D Lewis,
Jeffrey L Nordstrom,
Scott Koenig,
Paul A Moore,
Syd Johnson,
Ezio BonviniClin Cancer Res 2017 Mar 23;23(6):1506-1518. Epub 2016 Sep 23.Research, MacroGenics, Inc., Rockville, Maryland. March 2017




Download Full Paper











Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.
Authors:
Muneera Al-Hussaini,
Michael P Rettig,
Julie K Ritchey,
Darja Karpova,
Geoffrey L Uy,
Linda G Eissenberg,
Feng Gao,
William C Eades,
Ezio Bonvini,
Gurunadh R Chichili,
Paul A Moore,
Syd Johnson,
Lynne Collins,
John F DiPersioBlood 2016 Jan 3;127(1):122-31. Epub 2015 Nov 3.Division of Oncology, Department of Medicine, and.January 2016




Download Full Paper











A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates.
Authors:
Gurunadh R Chichili,
Ling Huang,
Hua Li,
Steve Burke,
Leilei He,
Qin Tang,
Linda Jin,
Sergey Gorlatov,
Valentina Ciccarone,
Francine Chen,
Scott Koenig,
Michele Shannon,
Ralph Alderson,
Paul A Moore,
Syd Johnson,
Ezio BonviniSci Transl Med 2015 May;7(289):289ra82MacroGenics Inc., 9640 Medical Center Drive, Rockville, MD 20850, USA. May 2015




Download Full Paper











Isolation of cancer stem like cells from human adenosquamous carcinoma of the lung supports a monoclonal origin from a multipotential tissue stem cell.
Authors:
Jennie P Mather,
Penelope E Roberts,
Zhuangyu Pan,
Francine Chen,
Jeffrey Hooley,
Peter Young,
Xiaolin Xu,
Douglas H Smith,
Ann Easton,
Panjing Li,
Ezio Bonvini,
Scott Koenig,
Paul A MoorePLoS One 2013  4;8(12):e79456. Epub 2013 Dec 4.MacroGenics, Inc., South San Francisco, California, United States of America.December 2013




Download Full Paper











Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial.
Authors:
William Hagopian,
Robert J Ferry,
Nicole Sherry,
David Carlin,
Ezio Bonvini,
Syd Johnson,
Kathryn E Stein,
Scott Koenig,
Anastasia G Daifotis,
Kevan C Herold,
Johnny Ludvigsson,
 Diabetes 2013 Nov 25;62(11):3901-8. Epub 2013 Jun 25.Pacific Northwest Diabetes Research Institute, Seattle, Washington.November 2013




Download Full Paper











C-reactive protein causes insulin resistance in mice through Fcγ receptor IIB-mediated inhibition of skeletal muscle glucose delivery.
Authors:
Keiji Tanigaki,
Wanpen Vongpatanasin,
Jose A Barrera,
Dmitriy N Atochin,
Paul L Huang,
Ezio Bonvini,
Philip W Shaul,
Chieko MineoDiabetes 2013 Mar 15;62(3):721-31. Epub 2012 Oct 15.Division of Pulmonary and Vascular Biology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.March 2013




Download Full Paper











Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
Authors:
Deryk Loo,
Ralph F Alderson,
Francine Z Chen,
Ling Huang,
Wenjun Zhang,
Sergey Gorlatov,
Steve Burke,
Valentina Ciccarone,
Hua Li,
Yinhua Yang,
Tom Son,
Yan Chen,
Ann N Easton,
Jonathan C Li,
Jill R Rillema,
Monica Licea,
Claudia Fieger,
Tony W Liang,
Jennie P Mather,
Scott Koenig,
Stanford J Stewart,
Syd Johnson,
Ezio Bonvini,
Paul A MooreClin Cancer Res 2012 Jul 21;18(14):3834-45. Epub 2012 May 21.MacroGenics, Inc., South San Francisco, CA, USA.July 2012




Download Full Paper











Nonclinical evaluation of GMA161--an antihuman CD16 (FcγRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice.
Authors:
Meghan M Flaherty,
Timothy K MacLachlan,
Misty Troutt,
Tomas Magee,
Nadine Tuaillon,
Syd Johnson,
Kathryn E Stein,
Ezio Bonvini,
Richard Garman,
Laura AndrewsToxicol Sci 2012 Jan 24;125(1):299-309. Epub 2011 Oct 24.Biologics Research and Development, Genzyme Corporation, Framingham, Massachusetts 01701-9322, USA.January 2012




Download Full Paper











Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Authors:
Nicole Sherry,
William Hagopian,
Johnny Ludvigsson,
Sunil M Jain,
Jack Wahlen,
Robert J Ferry,
Bruce Bode,
Stephen Aronoff,
Christopher Holland,
David Carlin,
Karen L King,
Ronald L Wilder,
Stanley Pillemer,
Ezio Bonvini,
Syd Johnson,
Kathryn E Stein,
Scott Koenig,
Kevan C Herold,
Anastasia G Daifotis,
 Lancet 2011 Aug 28;378(9790):487-97. Epub 2011 Jun 28.Massachusetts General Hospital, Boston, MA 02114, USA. August 2011




Download Full Paper











Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma.
Authors:
Paul A Moore,
Wenjun Zhang,
G Jonah Rainey,
Steve Burke,
Hua Li,
Ling Huang,
Sergey Gorlatov,
Maria Concetta Veri,
Sudeepta Aggarwal,
Yinhua Yang,
Kalpana Shah,
Linda Jin,
Sunan Zhang,
Leilei He,
Tengfei Zhang,
Valentina Ciccarone,
Scott Koenig,
Ezio Bonvini,
Syd JohnsonBlood 2011 Apr 7;117(17):4542-51. Epub 2011 Feb 7.MacroGenics Inc, Rockville, MD, USA. April 2011




Download Full Paper











Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.
Authors:
Jeffrey L Nordstrom,
Sergey Gorlatov,
Wenjun Zhang,
Yinhua Yang,
Ling Huang,
Steve Burke,
Hua Li,
Valentina Ciccarone,
Tengfei Zhang,
Jeffrey Stavenhagen,
Scott Koenig,
Stanford J Stewart,
Paul A Moore,
Syd Johnson,
Ezio BonviniBreast Cancer Res 2011  30;13(6):R123. Epub 2011 Nov 30.MacroGenics, Inc., 9640 Medical Center Drive, Rockville, MD 20850, USA. March 2011




Download Full Paper











Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold.
Authors:
Maria-Concetta Veri,
Stephen Burke,
Ling Huang,
Hua Li,
Sergey Gorlatov,
Nadine Tuaillon,
G Jonah Rainey,
Valentina Ciccarone,
Tengfei Zhang,
Kay Shah,
Linda Jin,
Lida Ning,
Tamara Minor,
Paul A Moore,
Scott Koenig,
Syd Johnson,
Ezio BonviniArthritis Rheum 2010 Jul;62(7):1933-43MacroGenics, Inc., Rockville, Maryland 20850, USA.July 2010




Download Full Paper











Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion.
Authors:
Syd Johnson,
Stephen Burke,
Ling Huang,
Sergey Gorlatov,
Hua Li,
Weili Wang,
Wenjun Zhang,
Nadine Tuaillon,
Jonah Rainey,
Bhaswati Barat,
Yinhua Yang,
Linda Jin,
Valentina Ciccarone,
Paul A Moore,
Scott Koenig,
Ezio BonviniJ Mol Biol 2010 Jun 9;399(3):436-49. Epub 2010 Apr 9.MacroGenics, Inc., 1500 East Gude Drive, Rockville, MD 20850, USA. June 2010




Download Full Paper











IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIB.
Authors:
Carol T Cady,
Maree S Powell,
Ronald J Harbeck,
Patricia C Giclas,
James R Murphy,
Rohit K Katial,
Richard W Weber,
P Mark Hogarth,
Syd Johnson,
Ezio Bonvini,
Scott Koenig,
John C CambierImmunol Lett 2010 May 30;130(1-2):57-65. Epub 2009 Dec 30.Division of Allergy & Immunology, National Jewish Health, Denver, USA.May 2010




Download Full Paper











The inhibitory Fc gamma IIb receptor dampens TLR4-mediated immune responses and is selectively up-regulated on dendritic cells from rheumatoid arthritis patients with quiescent disease.
Authors:
Mark H Wenink,
Kim C M Santegoets,
Mieke F Roelofs,
Richard Huijbens,
Hans J P M Koenen,
Ronald van Beek,
Irma Joosten,
Friederike Meyer-Wentrup,
Linda Mathsson,
Johan Ronnelid,
Gosse J Adema,
Ezio Bonvini,
Scott Koenig,
Wim B van den Berg,
Piet L C M van Riel,
Timothy R D J RadstakeJ Immunol 2009 Oct 4;183(7):4509-20. Epub 2009 Sep 4.Department of Rheumatology, Nijmegen Centre of Molecular Life Sciences and Radboud University Nijmegen Medical Centre, Geert Grooteplein 8, Nijmegen 6500 HB, The Netherlands. October 2009




Download Full Paper











C-reactive protein inhibits insulin activation of endothelial nitric oxide synthase via the immunoreceptor tyrosine-based inhibition motif of FcgammaRIIB and SHIP-1.
Authors:
Keiji Tanigaki,
Chieko Mineo,
Ivan S Yuhanna,
Ken L Chambliss,
Michael J Quon,
Ezio Bonvini,
Philip W ShaulCirc Res 2009 Jun 7;104(11):1275-82. Epub 2009 May 7.Division of Pulmonary and Vascular Biology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.June 2009




Download Full Paper











Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization.
Authors:
Jeffrey B Stavenhagen,
Sergey Gorlatov,
Nadine Tuaillon,
Christopher T Rankin,
Hua Li,
Stephen Burke,
Ling Huang,
Syd Johnson,
Scott Koenig,
Ezio BonviniAdv Enzyme Regul 2008  3;48:152-64. Epub 2007 Dec 3.MacroGenics, Inc., 1500 East Gude Drive, Rockville, MD 20850, USA. September 2008




Download Full Paper











CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy.
Authors:
Ping Zhou,
Raymond L Comenzo,
Adam B Olshen,
Ezio Bonvini,
Scott Koenig,
Peter G Maslak,
Martin Fleisher,
James Hoffman,
Suresh Jhanwar,
James W Young,
Stephen D Nimer,
Adam M BoruchovBlood 2008 Apr 23;111(7):3403-6. Epub 2008 Jan 23.Sloan-Kettering Institute, Department of Medicine, New York, NY 10021, USA.April 2008




Download Full Paper











Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Authors:
Jeffrey B Stavenhagen,
Sergey Gorlatov,
Nadine Tuaillon,
Christopher T Rankin,
Hua Li,
Stephen Burke,
Ling Huang,
Sujata Vijh,
Syd Johnson,
Ezio Bonvini,
Scott KoenigCancer Res 2007 Sep;67(18):8882-90MacroGenics, Inc., Rockville, Maryland 20850, USA. September 2007




Download Full Paper











Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization.
Authors:
Maria-Concetta Veri,
Sergey Gorlatov,
Hua Li,
Steve Burke,
Syd Johnson,
Jeffrey Stavenhagen,
Kathryn E Stein,
Ezio Bonvini,
Scott KoenigImmunology 2007 Jul 26;121(3):392-404. Epub 2007 Mar 26.MacroGenics Inc., Rockville, MD 20850, USA.July 2007




Download Full Paper











Intramolecular regulation of phospholipase C-gamma1 by its C-terminal Src homology 2 domain.
Authors:
Karen DeBell,
Laurie Graham,
Ilona Reischl,
Carmen Serrano,
Ezio Bonvini,
Barbara RellahanMol Cell Biol 2007 Feb 20;27(3):854-63. Epub 2006 Nov 20.Laboratory of Immunobiology, Division of Monoclonal Antibodies, Centrer for Drug Evaluation and Research, Food and Drug Administration/DHHS, 29 Lincoln Drive, Bethesda, MD 20892-4555, USA. February 2007




Download Full Paper











The functional variant of the inhibitory Fcgamma receptor IIb (CD32B) is associated with the rate of radiologic joint damage and dendritic cell function in rheumatoid arthritis.
Authors:
Timothy R D J Radstake,
Barbara Franke,
Mark H Wenink,
Karin C A M Nabbe,
Marieke J H Coenen,
Paco Welsing,
Ezio Bonvini,
Scott Koenig,
Wim B van den Berg,
Pilar Barrera,
Piet L C M van RielArthritis Rheum 2006 Dec;54(12):3828-37Department of Rheumatology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. December 2006




Download Full Paper











CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma.
Authors:
Christopher T Rankin,
Maria-Concetta Veri,
Sergey Gorlatov,
Nadine Tuaillon,
Steve Burke,
Ling Huang,
H David Inzunza,
Hua Li,
Shannon Thomas,
Syd Johnson,
Jeffrey Stavenhagen,
Scott Koenig,
Ezio BonviniBlood 2006 Oct 6;108(7):2384-91. Epub 2006 Jun 6.MacroGenics, Rockville, MD 20850, USA.October 2006




Download Full Paper











Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions.
Authors:
Adam M Boruchov,
Glenn Heller,
Maria-Concetta Veri,
Ezio Bonvini,
Jeffrey V Ravetch,
James W YoungJ Clin Invest 2005 Oct 15;115(10):2914-23. Epub 2005 Sep 15.Laboratory of Cellular Immunobiology, Hematology Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. October 2005




Download Full Paper











A new tyrosine phosphorylation site in PLC gamma 1: the role of tyrosine 775 in immune receptor signaling.
Authors:
Carmen J Serrano,
Laurie Graham,
Karen DeBell,
Rashmi Rawat,
Maria Concetta Veri,
Ezio Bonvini,
Barbara L Rellahan,
Ilona G ReischlJ Immunol 2005 May;174(10):6233-7Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, National Institutes of Health Campus, Bethesda, MD 20892, USA.May 2005




Download Full Paper











dlk acts as a negative regulator of Notch1 activation through interactions with specific EGF-like repeats.
Authors:
Victoriano Baladrón,
María José Ruiz-Hidalgo,
María Luisa Nueda,
María José M Díaz-Guerra,
José Javier García-Ramírez,
Ezio Bonvini,
Elena Gubina,
Jorge LabordaExp Cell Res 2005 Feb 2;303(2):343-59. Epub 2004 Nov 2.Biochemistry and Molecular Biology Branch, Department of Inorganic Chemistry, Organic Chemistry and Biochemistry, Medical School/RCBR (Regional Center for Biomedical Research), University of Castilla-La Mancha, Campus of Albacete, Avda. Almansa s/n, Spain.February 2005




Download Full Paper











Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells.
Authors:
Kavita M Dhodapkar,
Jacob L Kaufman,
Marc Ehlers,
Devi K Banerjee,
Ezio Bonvini,
Scott Koenig,
Ralph M Steinman,
Jeffrey V Ravetch,
Madhav V DhodapkarProc Natl Acad Sci U S A 2005 Feb 9;102(8):2910-5. Epub 2005 Feb 9.Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, New York, NY 10021, USA.February 2005




Download Full Paper











Biomarkers and surrogate endpoints in renal transplantation: present status and considerations for clinical trial design.
Authors:
Peter A Lachenbruch,
Amy S Rosenberg,
Ezio Bonvini,
Marc W Cavaillé-Coll,
Robert B ColvinAm J Transplant 2004 Apr;4(4):451-7Division of Biostatistics, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, FDA, Rockville, MD, USA.April 2004




Download Full Paper











A dynamic constitutive and inducible binding of c-Cbl by PLCgamma1 SH3 and SH2 domains (negatively) regulates antigen receptor-induced PLCgamma1 activation in lymphocytes.
Authors:
Barbara L Rellahan,
Laurie J Graham,
Alexander Y Tysgankov,
Karen E DeBell,
Maria-Concetta Veri,
Cristiana Noviello,
Ezio BonviniExp Cell Res 2003 Sep;289(1):184-94Laboratory of Immunobiology, Division of Monoclonal Antibodies, Center for Biologics Evaluation and Research, NIH, Bethesda, MD 20892, USA. September 2003




Download Full Paper











On the mechanism coupling phospholipase Cgamma1 to the B- and T-cell antigen receptors.
Authors:
Ezio Bonvini,
Karen E DeBell,
Maria-Concetta Verí,
Laurie Graham,
Bogdan Stoica,
Jorge Laborda,
M Javad Aman,
Angela DiBaldassarre,
Sebastiano Miscia,
Barbara L RellahanAdv Enzyme Regul 2003 ;43:245-69Division of Monoclonal Antibodies, Center for Biologics Evaluation & Research, US-FDA, HFM-564, NIH Campus, Bldg.29B/Rm.3NN10, 8800 Rockville Pike, Bethesda, MD 20892, USA. June 2003




Download Full Paper











70Z/3 Cbl induces PLC gamma 1 activation in T lymphocytes via an alternate Lat- and Slp-76-independent signaling mechanism.
Authors:
Laurie J Graham,
Maria-Concetta Verí,
Karen E DeBell,
Cristiana Noviello,
Rashmi Rawat,
Sandy Jen,
Ezio Bonvini,
Barbara RellahanOncogene 2003 Apr;22(16):2493-503Laboratory of Immunobiology, Division of Monoclonal Antibodies, Center for Biologics Evaluation and Research, Bethesda, MD 20892, USA.April 2003




Download Full Paper











The EGF-like homeotic protein dlk affects cell growth and interacts with growth-modulating molecules in the yeast two-hybrid system.
Authors:
Victoriano Baladrón,
María José Ruiz-Hidalgo,
Ezio Bonvini,
Elena Gubina,
Vicente Notario,
Jorge LabordaBiochem Biophys Res Commun 2002 Feb;291(2):193-204Laboratory of Immunobiology, Division of Monoclonal Antibodies, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, Maryland 20852, USA.February 2002




Download Full Paper











Tumor necrosis factor alpha (TNF-alpha) activates Jak1/Stat3-Stat5B signaling through TNFR-1 in human B cells.
Authors:
Sebastiano Miscia,
Marco Marchisio,
Alfredo Grilli,
Valentina Di Valerio,
Lucia Centurione,
Giuseppe Sabatino,
Francesco Garaci,
Giorgio Zauli,
Ezio Bonvini,
Angela Di BaldassarreCell Growth Differ 2002 Jan;13(1):13-8Cell Signaling Unit, Department of Biomorphology, School of Medicine, University of Chieti, 66100 Chieti, Italy. January 2002




Download Full Paper



 






















 OF 













Ezio  Bonvini - CEO, founder, businessman - profile

















directorpedia.net - List of CEOs, founders, board members and company directors











Ezio  Bonvini
Check out list of companies and businesses related to Ezio  Bonvini. Find out Ezio  Bonvini address and contact details. View other people related to Ezio  Bonvini - coworkers, colleagues, companions, etc.
Address:   

C/O MACROGENICS, INC. 9640 MEDICAL CENTER DRIVE ROCKVILLE 20850 MD




Companies related to Ezio  Bonvini
CIKCompany NamePositionCompany Address0001125345MACROGENICS INCSr VP, Research & CSO 9704 MEDICAL CENTER DRIVE  Rockville 20850




Ezio  Bonvini on the Web
Persons related to Ezio  Bonvini - MACROGENICS INCNamePositionCityALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KGSAN FRANCISCOALTA BIOPHARMA PARTNERS III LP10% Owner SAN FRANCISCOALTA EMBARCADERO BIOPHARMA PARTNERS III LLCSAN FRANCISCOOronsky  ArnoldRockvilleDAVID  BONDERMANFORT WORTHEzio  BonviniSr VP, Research & CSO ROCKVILLEEzio  BonviniSenior VP, Research ROCKVILLEHARVEY B  CASHMENLO PARKLynn  CilinskiVP, Controller and Treasurer ROCKVILLELynn  CilinskiVP, Controller and Treasurer ROCKVILLEPaulo F  CostaDirector SAN DIEGOPaulo F  CostaDirector ROCKVILLEJAMES G  COULTERFORT WORTHHurwitz  EdRockvilleKaren Jean  FerranteDirector TARRYTOWNMatthew K  FustDirector PALO ALTOKenneth  GalbraithDirector PRINCETONKenneth  GalbraithDirector ROCKVILLEPHILIP T  GIANOSMENLO PARKW SCOTT  HEDRICKMENLO PARKW Stephen  HolmesMENLO PARKEDWARD  HURWITZDirector SAN FRANCISCOEDWARD  HURWITZDirector ROCKVILLEINTERWEST INVESTORS Q VIII LPMENLO PARKINTERWEST INVESTORS VIII L PMENLO PARKInterWest Management Partners VIII, LLCMENLO PARKINTERWEST PARTNERS VIII LP10% Owner MENLO PARKScott Thomas  JacksonDirector PRINCETONKarrels  JamesRockvilleJames  KarrelsSVP, CFO and Secretary ROCKVILLEJames  KarrelsVP, CFO and Secretary ROCKVILLEGalbraith  KenRockvilleGilbert H  KlimanMENLO PARKScott  KoenigPresident and CEO ROCKVILLEScott  KoenigPresident and CEO ROCKVILLESteinmetz  MichaelRockvilleEran  NadavFORT WORTHEran  NadavDirector ROCKVILLEARNOLD L  ORONSKYDirector ROCKVILLESekhri  PaulRockvilleCosta  PauloRockvilleJeffrey Stuart  PetersROCKVILLEEric Blasius  RisserSr VP & Chief Business Officer ROCKVILLEEric Blasius  RisserVP, Business Development ROCKVILLEEric Blasius  RisserVP, Business Development ROCKVILLEATUL  SARANSVP & General Counsel MONROVIAATUL  SARANROCKVILLEATUL  SARANSr. VP and General Counsel ROCKVILLEKoenig  ScottRockvilleThomas  SpitznagelSr VP, BPD & Manufacturing ROCKVILLEKathryn E  SteinSVP, Product Dev. & Regulatory ROCKVILLEKathryn E  SteinSVP, Product Dev. & Regulatory ROCKVILLEStanford John  StewartV P, Clinical Oncology ROCKVILLEDAVID C  STUMPDirector ROCKVILLEDAVID C  STUMPDirector ROCKVILLETPG Group Holdings (SBS) Advisors, Inc. FORT WORTHJon Marc  WiggintonSr VP, Clinical Dev. & CMO ROCKVILLEJon Marc  WiggintonSr VP, Clinical ROCKVILLE












 






